DALLAS, Aug. 3, 2004 (PRIMEZONE) -- Mosaic Nutraceuticals (Pink Sheets:MCNJ) today announced that they will introduce Celaprix, their proprietary, OTC osteoarthritis and pain relief topical rub, for retail distribution effective September first. Mosaic Nutraceuticals plans to support the launch of Celaprix with a multi-million dollar advertising campaign.
Celaprix is a highly effective topical rub that has been shown to reduce pain as well as help naturally reverse the effects of osteoarthritis. Celaprix contains a proprietary combination of two main ingredients called celadrin and boswellian extract. Celadrin has been clinically tested and shown to help reverse osteoarthritis, enhance joint ROM and reduce pain (the results of this clinical study were published in the Journal of Rheumatology).
Osteoarthritis is considered "wear and tear" arthritis, and it is a major health problem effecting America. It is currently estimated that 20.7 million Americans currently suffer from osteoarthritis and that osteoarthritis is responsible for a minimum of 7 million physician visits per year.
President of Mosaic Nutraceuticals, Charlie Townsend, said, "Last month we introduced Lipotrene, a proprietary, sugar-free, low-carbohydrate candy chew containing the specific active ingredient policosanol, which is extracted from the wax of sugar cane and has been shown in clinical studies to reduce cholesterol levels naturally by as much as 20%.
Today we are extremely excited about the launch of Celaprix. Celaprix is an important product addition to the growing Mosaic family. The benefits consumers can experience from using Celaprix are truly amazing. We firmly believe that osteoarthritis sufferers should look to Celaprix for lasting relief before resorting to prescription treatments."
Mosaic Nutraceuticals is located in Dallas, Texas, and its mission is to help enhance and improve the quality of life of its consumers through cutting-edge, highly unique dietary supplements and products. Mosaic plans to be a market leader in the nutritional field and will strive to grow its product line through dynamic innovation and acquisitions. The categories Mosaic plans to focus on include: Osteoarthritis, pain relief; low-carbohydrate functional foods, cholesterol health, weight loss/appetite suppression, anti-aging and general wellness.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the company with the Securities and Exchange Commission. The company cannot guarantee its future results, levels of activity, performance or achievements.
More information may be obtained by contacting Charles Townsend at www.mosaicnutracorp.com.
HTML: http://newsroom.eworldwire.com/wr/080304/10485.htm PDF: http://newsroom.eworldwire.com/pdf/080304/10485.pdf ONLINE NEWSROOM: http://newsroom.eworldwire.com/2508.htm LOGO: http://newsroom.eworldwire.com/2508.htm